



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtivision.com

www.vtivisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

Atlanta, Georgia, USA 21 January 2018 (22 January 2018 AT): Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) Contact Lenses has today released its Appendix 4C - Quarterly Cash Flow for the period ended 31 December 2017 (fourth quarter FY17).

The Company reported pre-audited 4Q17 sales revenue of US\$395,795, a 12% increase over 3Q17 revenue (\$354,322), bringing 2017 revenue to US\$1,048,978. The Company finished the quarter and the year with 730 active accounts (eye care professionals that purchased during the quarter). This represents an increase of 38% compared to the 528 active accounts at the end of 3Q17, continuing the trend of growth. Fourth-Quarter revenue growth overcame normal industry seasonality, in which 4Q revenue is usually less than 3Q.

Net operating cash outflow for the quarter was US\$3,184,000, compared to the previous period ended 30 September 2017 net operating cash outflow of US\$3,470,000. Cash receipts from customers for the quarter were US\$420,000, for the year were \$829,000, and end of quarter cash on hand was US\$16,584,000.

In 2018, the Company plans to continue expanding the availability of its flagship product, NaturalVue Multifocal. Additionally, technological advancements to NaturalVue Toric are being tested, and NaturalVue Toric is expected to launch late in 2018. Likewise, improvements to NaturalVue Sphere are being undertaken, and launch of a next-generation NaturalVue Sphere is expected mid-late 2018. NaturalVue Multifocal Toric is expected to launch 1H2019.

The Company's sales force has grown to 25 sales representatives (a.k.a. "Territory Managers"). The Company plans to reach approximately 45 territory managers by mid-2018, and expects that a new territory targeted by a territory manager will reach revenue maturity over a period of 2 to 4 years from hiring.

Cash outflows in 1Q2018 are expected to increase to approximately US\$4,981,000 from approximately \$3,604,000 in 4Q2017, mostly due to the on-going inventory and sales and marketing expansion in the United States.

Dr. Stephen Snowdy, CEO and Executive Director of Visioneering, commented, "It has been an excellent year of expansion at VTI. We've grown from 5 territory managers to 25 territory managers, hiring some of the most talented sales professionals in the eyecare industry. As

anticipated, we are already seeing strong growth in the number of active accounts, which is translating nicely into revenue as awareness of the benefits of NaturalVue MF increases among eye care professionals. We have also obtained new patents, seen the publication of a peer-reviewed study finding that NaturalVue MF lenses reduced myopia progression in children, and have set the stage for international expansion in 2018. We are pleased with our progress in 2017, and we are looking forward to 2018.”

Investor Conference Call

Investors are invited to join a conference call on Tuesday 23 January at 9.00am AEDT (Monday 22 January 5.00pm EST) hosted by Visioneering Technologies CEO Stephen Snowdy.

To pre-register for the call please use this link:

<https://services.choruscall.com.au/diamondpass/vtivision-238877-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternatively you can dial in using the details below at the scheduled call start time.

Conference ID: 238 877

Participant Dial In Numbers

Australia Toll Free: 1 800 558 698

Australia Local: 02 9007 3187

New Zealand Toll Free: 0800 453 055

Hong Kong: 800 966 806

Singapore: 800 101 2785

United Kingdom: 0800 051 8245

United States: (855) 881 1339

United Kingdom: 0800 051 8245

US Local (New York): (914) 202 3258

US Local (Los Angeles): (909) 235 4020

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in

two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHESS Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR21 r1

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Visioneering Technologies, Inc.

ABN

616 156 248

Quarter ended ("current quarter")

December 31, 2017

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (12months) US\$'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	420	829
1.2	Payments for		
	(a) research and development	(176)	(542)
	(b) product manufacturing and operating costs	(793)	(4,352)
	(c) advertising and marketing	(223)	(844)
	(d) leased assets	-	-
	(e) staff costs	(1,949)	(5,401)
	(f) administration and corporate costs	(506)	(2,060)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	43	87
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(3,184)	(12,283)
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(37)	(158)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	(27)	(43)
	(e) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (12months) US\$'000
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(64)	(201)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	25,951
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(2,557)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	23,394
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	19,832	5,674
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,184)	(12,283)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(64)	(201)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	23,394
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	16,584	16,584

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1 Bank balances	250	250
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (#)	16,334	19,582
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	16,584	19,832

U.S. Treasury bills, notes, and other high-quality, short term securities that are issued or guaranteed by the U.S. government or by U.S. government agencies.

6. Payments to directors of the entity and their associates	Current quarter US\$'000
6.1 Aggregate amount of payments to these parties included in item 1.2	73
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7. Payments to related entities of the entity and their associates	Current quarter US\$'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available
Add notes as necessary for an understanding of the position

	Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

9. Estimated cash outflows for next quarter	US\$'000
9.1 Research and development	329
9.2 Product manufacturing and operating costs	1,094
9.3 Advertising and marketing	480
9.4 Leased assets	
9.5 Staff costs	2,652
9.6 Administration and corporate costs	426
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	4,981

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	N/A	N/A
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Sign here: 
 (Director/Company secretary)

Date: 21 Jan 2018

Print name: Stephen Snowdy

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.